ELDN

Announcements

Nothing here yet

Daily updates

• Eledon reported updated Phase 2 BESTOW extension data showing tegoprubart maintained statistically higher kidney function than tacrolimus through 24 months, with mean eGFR of 71 versus 58 mL/min/1.73 m².Sep 22, 2026

FDA designations

Nothing here yet

News

• NewcelX reported a successful FDA pre-IND meeting, clearing the path for NCEL-101 clinical trials in type 1 diabetesJul 2, 2026
• Eledon presented long-term Phase 2 BESTOW extension results showing improved kidney function and patient outcomes with tegoprubart versus tacrolimusJun 22, 2026
• Eledon Pharmaceuticals to present new long-term Phase 2 BESTOW data for tegoprubart in kidney transplant rejection preventionMay 21, 2026
• NewcelX updated its presentation highlighting its type 1 diabetes program after strategic collaboration with Eledon PharmaceuticalsApr 20, 2026
• Eledon presented updated data from an investigator-initiated islet transplant study of tegoprubart in type 1 diabetesMar 16, 2026